Latest disclosed round
Series B
- Date
- 2021-11-01
- Amount
- USD 156m
- Sector
- Biotech & techbio
- Companies House
- 11890040
Series B
Quell Therapeutics
Cell therapy (engineered T-regulatory cells)
CandidateSeries BLondon
Evidence status
Review retained
- Identity
- Candidate
- Match
- High candidate
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
6 linked investors
Funding record
1 disclosed round
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2021-11-01 | Series B | $156M | Jeito Capital, Ridgeback Capital Investments, SV Health Investors, Fidelity Management & Research Company, Syncona |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.